Genotyping Assay Market worth $44.60 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global genotyping assay market will grow from USD 24.29 billion in 2026 to USD 44.60 billion by 2031, a 12.9% CAGR. The report cites sequencing advances, personalized medicine and genomic research as growth drivers; sequencing is projected to be the fastest-growing technology segment. It also highlights genomic-sector funding, including Element Biosciences’ USD 175 million investment from Samsung in June 2026, and QIAGEN’s USD 70 million acquisition of Genoox, with up to USD 10 million in milestone payments.

Analysis

The headline growth forecast is a vendor estimate, not evidence of incremental earnings: market definitions may combine research, clinical testing, services, and consumables, with different adoption and pricing curves. The investable question is whether sequencing expansion adds recurring reagent and workflow revenue or simply shifts spend from arrays and PCR. If lower sequencing costs broaden test volumes, consumables and sample-preparation providers could capture repeat sales; instrument growth alone is less compelling if utilization or assay pull-through disappoints. More sequencing also pushes value toward interpretation software and clinical validation, but creates a bottleneck in reimbursement, data quality, and clinical adoption.

Near term, treat the release as weak sentiment support rather than a catalyst for a sector re-rating. Over 1–3 months, look for company disclosures on genomics consumables growth, instrument utilization, and pharma/clinical demand. Over 6–18 months, adoption and reimbursement—not the forecast CAGR—will determine whether the mix shift supports durable revenue.

Potential relative beneficiaries include Thermo Fisher Scientific and QIAGEN through recurring workflows, while Illumina has exposure to sequencing-platform adoption but also faces substitution and utilization risk if demand fails to follow installed capacity. QIAGEN’s Genoox acquisition could strengthen interpretation offerings, though financial contribution is unverified. Danaher and Eurofins have possible exposure through broader life-sciences/diagnostics and genomics services, respectively; the article does not establish material earnings sensitivity for either. Key reversal risks are slower clinical uptake, price compression, weak research funding, and sequencing growth that cannibalizes legacy assays without increasing total test volumes. Contrarian point: the market may be over-crediting technology adoption and underweighting reimbursement, workflow integration, and proof of consumables pull-through.

Key Decisions for Investors

• No immediate broad genomics long based on this press release. The forecast’s scope, methodology, and company-level revenue bridge are not independently verified; avoid translating category growth directly into listed-company earnings.
• Set an earnings-triggered watch on Thermo Fisher Scientific and QIAGEN: consider relative longs only if reported consumables or molecular/genomics growth and guidance confirm recurring demand, rather than relying on instrument or market-growth commentary. Falsify on slowing relevant product growth or weaker guidance.
• Keep Illumina as a conditional relative underweight versus diversified life-science exposure if sequencing volumes or consumables pull-through disappoint; do not initiate solely on the forecast. Reassess if utilization, sequencing-related revenue, and customer demand accelerate in reported results.
• Monitor reimbursement decisions, clinical test volumes, and pharma-genomics adoption over the next 1–3 months, then reassess over 6–18 months. These are missing data points needed to size exposure; a material reimbursement setback or sustained assay price compression would invalidate the adoption thesis.